Philip T. Sager, M.D.

Dr. Sager is a Consulting Professor of Medicine at the Stanford University School of Medicine, a Voting Member of FDA Cardiovascular and Renal Drugs Advisory Committee, a member of the ICH E14 Discussion Group, and a private pharmaceutical and device consultant.  He chairs the Scientific Programs Committee of the Cardiac Safety Research Consortium.  Previous roles have included Vice President, CV/Metabolic Development at Gilead Sciences, Chief Medical Officer at CardioDx, Executive Director at AstraZeneca, and tenured faculty member in Cardiology at the UCLA School of Medicine. Dr. Sager is a Fellow of the American College of Cardiology, a Fellow of the American Heart Association, a Fellow of the Heart Rhythm Society, and is a member of the Board of Directors of Anthera, Inc..  He holds an M.D. from Yale University School of Medicine, B.S. degrees from the Massachusetts Institute of Technology and has published more than 150 manuscripts and abstracts.